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SUMMARY
Megakaryocytes (Mgks) are terminally differentiated blood cells speciﬁed to produce platelets, whereas hematopoietic stem cells
(HSCs) are the most undifferentiated blood cells that retain multipotency to produce all kinds of blood cells. As such, these two cell
types reside at the bottom and the top of the hematopoietic hierarchy, respectively. In spite of this distance, they share several
important cell surface molecules as well as transcription factors.
In the conventional step-wise differentiation model, HSCs gradually lose their self-renewal capacity and differentiate into multipo-
tent progenitors (MPPs), which is the ﬁrst branch point of myeloid and lymphoid lineage. In this model, common myeloid progeni-
tors can differentiate into bipotent Mgk/erythroid progenitors (MEPs), and MEPs eventually differentiate into unipotent mature
Mgks. However, it has been recently reported that a subpopulation within the HSC and MPP compartments demonstrates an Mgk-
biased differentiation potential. These reports imply that revisions to the HSC-to-Mgk differentiation pathway should be discussed.
In this review, we summarize recent ﬁndings about Mgk differentiation from HSCs and discuss future directions in this research ﬁeld.
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SIGNIFICANCE STATEMENT
Transplant experimental models and single-cell analysis data reveal that the hematopoietic stem cell (HSC) compartment con-
tains a subpopulation with megakaryocyte (Mgk) lineage-biased potential. Mgk-biased progenitor cells also can be detected in
the multipotent progenitor fraction, suggesting that Mgks could emerge through a non-step-wise differentiation pathway from
HSCs, especially in stress-induced hematopoiesis.
INTRODUCTION
The hematopoietic system constantly generates a precise number
of blood cells with diverse functions. These functions are main-
tained by hematopoietic stem cells (HSCs), characterized by self-
renewal capacity and multipotent differentiation potential. This
rare subpopulation of blood cells provides a huge number of
peripheral blood cells throughout an individual’s lifetime [1].
Platelets are small, anucleated fragments of blood cells that
are generated from polypoid megakaryocytes (Mgks) and play a
critical role in homeostasis [2]. In the classical “step-wise” hier-
archical hematopoiesis model, HSCs produce committed progeni-
tors with decreasing self-renewal capacity and restricted lineage
differentiation potential. The bifurcation of myeloid/lymphoid line-
ages ﬁrst occurs within multipotent progenitors (MPPs) during dif-
ferentiation. The myeloid lineage progenitors further lose
differentiation potential into granulocyte/macrophage and ery-
throid linages and eventually produce unipotent Mgk progenitors
(MKPs) [3]. This differentiation model simpliﬁes the complexity of
the hematopoietic system and has been widely accepted over the
past decades. However, recent studies with novel prospective
isolation techniques and single-cell functional/molecular analyses
of HSCs and Mgks have revealed that these two cell types share a
remarkable number of surface molecules, transcription factors,
and cytokine signaling pathways. This suggests that Mgk might be
directly differentiated from HSC, possibly bypassing the Mgk/ery-
throid progenitor (MEP) stage [4]. In this paper, we summarize the
recent ﬁndings within the topic of megakaryopoiesis and propose
a revised road map for Mgk lineage differentiation.
SHARED SURFACE RECEPTORS, SIGNALING, AND GENE
EXPRESSION PROFILES IN HEMATOPOIETIC STEM CELLS AND
COMMITTED MGK LINEAGE CELLS
HSCs and Mgks share many common features, as previously
described (Fig. 1) [4]. As an example, the thrombopoietin (TPO)
signaling is one of the most essential cytokine signaling pathways
in both HSCs and Mgks. TPO was originally identiﬁed as a critical
growth factor for platelet production [5]. However, studies using
Mpl
-/- mice demonstrated that Mpl, which is a TPO receptor, also
plays an essential role for maintenance of HSCs [6]. HSCs derived
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PERSPECTIVES
from Mpl-/- mice showed a signiﬁcantly reduced long-term repo-
pulating capacity, suggesting that TPO/Mpl signaling is functionally
essential in HSC activity [6]. Another study demonstrated an indis-
pensable role of TPO/Mpl signaling in HSC quiescence [7]. In
humans, congenital defects or a loss-of-function mutation of Mpl
causes severe thrombocytopenia, called congenital amegakaryo-
cytic thrombocytopenia (CAMT). Patients with CAMT have a high
risk of bone marrow failure, suggesting that TPO/Mpl signaling is
also important for maintenance of human HSCs [4]. These data
imply that TPO/Mpl signaling might play a critical bridging role
between HSCs and Mgks. In addition, other shared signaling path-
ways between HSCs and Mgks, including CXCR4/CXCL12 [[8], [9]],
Notch [10, 11], and Stem cell factor/c-Kit signaling [12], have also
been reported [4].
Furthermore, various surface molecules are co-expressed on
HSCs/MPPs and Mgks. Indeed, the majority of surface markers so
far used for isolation of MKPs, such as CD150 [13], CD41 [14], and
CD9 [15], are also expressed in the entire population of, or a frac-
tion of, HSCs. CD150, known as SLAM1, is widely used for
puriﬁcation of mouse HSCs [13] and is also expressed on Mgk line-
age cells, including MKPs and platelets [16]. CD41 (integrin aIIb)
non-covalently associates with CD61 (integrin b3) to form the
integrin aIIbb3 complex on Mgks and platelets [4], which plays a
critical role in thrombus formation [17]. Additionally, CD41 is
expressed on the surface of a subpopulation of long-term HSCs
(LT-HSCs) and MPPs in mice. CD41 expression in Lineage-Sca11/c-
Kit1 mouse hematopoietic stem/progenitor fraction (LSK)
increases with aging and is related to the myeloid differentiation
potential of HSCs [14, 18]. From the similar expression pattern of
these molecules arises the possibility that Mgks may directly dif-
ferentiate from HSC.
In a closely associated context, a subpopulation of HSCs was
reported to express mRNA of von Willebrand factor (vWF) [19],
which is mainly found on the surface of injured endothelial cells,
mature Mgks, and platelets. On the other hand, CD42b, which is
the vWF receptor, was believed to be exclusively expressed on the
surface of Mgks and platelets [16]. Unlike CD41, immature pro-
genitor cells such as MPPs and LT-HSCs do not express CD42b in
Figure 1. Shared surface receptors and signaling in HSCs, Mgk-biased HSCs, and committed Mgks. In the immunophenotypic HSC compart-
ment (mainly the CD411 subpopulation), Mgk-biased HSCs exist. HSCs, Mgk-biased HSCs, and MKPs share several surface molecules. Tran-
scripts of Mgk-related genes, such as Vwf or CD42b, can be detected in Mgk-biased HSCs, but protein synthesis is inhibited in the steady
state. External signaling such as inﬂammatory cytokine or TPO/Mpl signaling can trigger protein synthesis, induce Mgk lineage differentiation,
and generate adequate numbers of platelets during emergency thrombocytosis. Abbreviations: HSC, hematopoietic stem cell; Mgk, megakar-
yocyte; MKP, Mgk progenitor; TPO, thrombopoietin.
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steady-state conditions [16]. Despite such a classical view, we
demonstrated CD42b surface expression in a CD34-/CD411/
CD1501 LSK population, a subset of HSCs, at the hematopoietic
recovery phase after 5-ﬂuorouracil treatment, prompting further
investigation [16]. Indeed, single-cell gene expression analysis
revealed that a subpopulation of CD411LSK expresses nuclear
CD42b mRNA even in the steady state [16], although it was not
clear whether nuclear CD42b mRNA-positive CD411 LSKs were
functional LT-HSCs. Furthermore, recent improvement of single-
cell RNA sequencing techniques enables comprehensive gene
expression analyses at single-cell resolution [20]. Whole transcrip-
tome analysis using single puriﬁed HSCs demonstrated that a sub-
population of HSC compartment expresses Mgk-speciﬁc genes
[21].
Another group demonstrated the regulatory mechanism of
the expression of Mgk-related genes in HSCs [22]. They showed
that the phenotypic HSC compartment contains stem-like Mgk
lineage-committed progenitors (SL-MKPs), which share similar
characteristics with HSCs but retain platelet-restricted differentia-
tion capacity. SL-MKPs reside in the CD411 subpopulation of phe-
notypic HSC and express Mgk-speciﬁc mRNAs while translation of
these mRNAs into protein is suppressed in SL-MKPs in the steady
state. Inﬂammation signals, such as activation of the interferon
signaling pathway, trigger Mgk differentiation and platelet produc-
tion through Mgk-speciﬁc mRNA translation in SL-MKPs. The
authors of this paper conclude that cell-cycle regulators such as
p27 and p57 under strict control of FoxO3a suppress translation
of such Mgk-speciﬁc mRNAs in the steady state [22]. Although fur-
ther investigation is required, transcriptional/translational regula-
tion of Mgk-speciﬁc genes in the HSC compartment may be a key
to understand underlying mechanisms in the commitment to Mgk
lineage from HSCs.
MGK LINEAGE COMMITMENT WITHIN THE HSC COMPARTMENT
Heavily shared molecular markers between HSCs and Mgks have
raised the possibility that Mgk lineage speciﬁcation could occur at
a more immature stage than that postulated in the classical step-
wise differentiation model [4]. In the adult mouse hematopoietic
system, HSCs are signiﬁcantly enriched in either CD34-/lowLSK [1]
or CD1501/CD48- LSK cells [13]. In the classical differentiation
model, the most immature myeloid progenitors, deﬁned as com-
mon myeloid progenitors (CMPs), are derived from MPP and dif-
ferentiate into bipotent granulocyte/macrophage progenitors and
MEPs, the latter of which eventually differentiate into MKPs while
losing their capacity to differentiate into the erythroid lineage
(Fig. 2A) [3]. However, it was recently reported that a phenotypic
CMP population is highly heterogeneous when analyzed by single-
cell RNA sequencing, while Mgk-speciﬁc genes, particularly tran-
scription factors, are detected in a subpopulation of CMPs, but
not in MEPs [23]. Indeed, we demonstrated that a CD42b-positive
subpopulation of CMPs represents unipotent MKPs [16]. CMPs
could be a mixture of heterogeneous progenitors such as unipo-
tent myeloid and Mgk progenitors, which may support the con-
cept that Mgk lineage commitment occurs at stages close to HSCs.
There are multiple lines of evidence showing that the mega-
karyopoietic pathway is bifurcated earlier than assumed in the
classical model (Fig. 2B) [10, 19, 24, 25]. Flt31LSKs are character-
ized as lymphoid-primed multipotent progenitors (LMPPs), which
notably lose Mgk/erythroid differentiation potential, retaining
granulocyte/macrophage potential [24]. While Mgk/erythroid dif-
ferentiation potential from LMPPs has been shown before, the
actual capacity of LMPPs to produce Mgk is reportedly signiﬁ-
cantly lower than that of HSCs or MPPs [18, 26, 27]. Additionally,
it was reported that Notch signaling plays an important role in
Mgk lineage speciﬁcation from HSCs in an in vitro co-culture sys-
tem [10]. In this report, the authors suggested that Notch signal-
ing promotes the alternative Mgk differentiation pathway from
HSCs, which could bypass the MEP stage.
More recently, several studies using novel single-cell func-
tional analysis methods suggested that mouse LT-HSC populations
are functionally heterogeneous and the commitment into Mgk lin-
eage is already made within a subpopulation of the LT-HSC com-
partment (Fig. 2C) [25]. Indeed, 10%–15% of the highly puriﬁed
LT-HSC population can directly differentiate into Mgk without cell
division in single-cell in vitro culture. The same population also
includes highly proliferating cells producing 100–1,000 single-
lineage Mgks [16, 25, 28]. Furthermore, the paired daughter assay
shows Mgks can be differentiated from HSCs even at the ﬁrst cell
division [25]. Although in vitro assays do not always perfectly sim-
ulate in vivo hematopoiesis, these data do support the possibility
that the subpopulation of HSCs possesses Mgk-biased/restricted
capacity, and Mgks may directly differentiate from them.
Data from a single-cell transplant report demonstrated that
puriﬁed HSC populations (CD34-LSK) contain several lineages of
biased HSCs, such as myeloid-biased, lymphoid-biased, and Mgk/
erythroid-biased HSCs [25]. These data implied that fate decision
to a speciﬁc lineage from multipotent HSCs might be made at the
LT-HSC level and also suggested that conventional, step-wise, hier-
archal, hematopoietic differentiation models might need to be
revised. They also demonstrated that the CD1501/CD411 subpo-
pulation of a mouse LT-HSC population (CD1501/CD411/CD34-
LSK) contains Mgk-restricted repopulating cells (MKRPs), which
showed restricted Mgk/platelet differentiation capacity and self-
renewal capacity in vivo. SL-MKPs (as discussed previously) also
reside as a subpopulation of the CD411LT-HSC population
(CD41med/CD1501/CD48-/c-Kit1/Lin-) [22]. Indeed, our single-cell
culture data revealed that the frequency of pure Mgk colonies
from the CD1501/CD411 LSK population was much higher than
that of the CD41-LSK population [16]. We also demonstrated that
continuous TPO/Mpl signaling was key for Mgk differentiation
from HSCs, bypassing bipotent MEPs [16]. Additional clarity comes
from studies (using Vwf as a genetic marker) that showed a sub-
population of Vwf-positive HSCs that possesses Mgk-biased differ-
entiation capacity and resides at the apex of the HSC hierarchy;
these cells expand within the HSC compartment during aging [19,
21]. These data also supported the concept that the fate decision
of the Mgk lineage is made at the LT-HSC level. Our group also
demonstrated that the CD1501/CD411LSK population expresses
Vwf at the single-cell level, and the CD411LSK subpopulation
showed exclusively high Mgk differentiation capacity [16].
Shin and colleagues reported that c-Kithigh1HSC (CD1501/
CD34-LSK) showed impaired self-renewal activity and megakaryo-
cytic bias [29]. This population produces Mgks and platelets more
rapidly in vitro and in vivo, and c-Kitlow HSCs were shown to be
more primitive and quiescent than c-Kithigh1HSCs, implying that
the Mgk-biased subpopulation of HSCs was not at the apex of the
hematopoietic hierarchy [29]. To clarify, if two distinct subsets of
Mgk-biased HSCs exist at the apex and the sub-apex of the hema-
topoietic system, further investigation is required. In actuality,
these concepts were mainly based on data from transplant/
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culture using a puriﬁed subpopulation of HSCs, which only
reﬂected the highly stressed hematopoietic condition.
According to the results from a Flt3 lineage tracing a mouse
model that genetically marks the progeny of Flt3-expressing cells,
all lineages (including platelets and erythrocytes) can be produced
from Flt31hematopoietic progenitors like the LMPP fraction in
vivo [30]. Although the possibility of transient ﬂt3 promoter acti-
vation at the HSC level might be a concern, the fate decision
mechanism that speciﬁes lineage from HSCs in the steady state
might be different from stress conditions such as hematopoietic
reconstitution after transplant or chemotherapy. Further analyses
would be needed for understanding platelet generation from
steady-state HSCs.
MEGAKARYOCYTOPOIESIS IN THE HUMAN
HEMATOPOIETIC SYSTEM
The classical, stepwise hematopoietic differentiation model has
been widely accepted to be the same in humans as in mice [31].
However, an alternative differentiation model was also suggested
in the human hematopoietic system, which would mirror the
mouse system [32, 33]. Using human cord blood and bone marrow
cells, single-cell analysis similarly revealed that the Mgk lineage
fate decision was made within the CD341/CD38-HSC-enriched
compartment and that the CD341/CD381CMP/MEP populations
are both heterogeneous [34], retaining less differentiation capacity
into Mgks [32]. They also demonstrated that Mgks are generated
from intermediate oligopotent progenitors in human fetal hemato-
poiesis, suggesting that the Mgk lineage differentiation systems in
fetal liver and adult bone marrow are distinct from each other
[32]. Further studies are required to prove the existence of Mgk-
biased HSCs or progenitor cells in the human hematopoietic sys-
tem, given that in vivo functional analysis at the single-cell level is
much more difﬁcult in humans than in mice [35].
CONCLUSION
Several recent studies demonstrated that the commitment to the
Mgk lineage is decided at a much earlier stage than previously
expected. The existence of lineage-biased HSCs, including Mgk-
Figure 2. The models of Mgk differentiation from HSCs. (A): The classical “step-wise” hierarchical hematopoiesis model. The bifurcation of
myeloid/lymphoid lineage ﬁrst occurs in MPPs, and MKPs eventually generate from MEPs as the progeny of CMPs. (B): Alternative model
based on the identiﬁcation of LMPPs. The bifurcation of Mgk lineage ﬁrst occurs during differentiation from HSCs. LMPPs lose almost all
Mgk/erythroid differentiation potential. (C): Proposed model from recent reports. An immunophenotypic-deﬁned HSC population contains a
functionally heterogeneous, Mgk-biased/restricted subpopulation of HSCs that directly gives rise to MKPs and bypassse the MEP stage.
Abbreviations: CLP, common lymphoid progenitor; CMP, common myeloid progenitor; Ery, erythroid; HSC, hematopoietic stem cells; LMPP,
lympho-myeloid primed progenitor; LT-HSC, long-term hematopoietic stem cells; MEP, Mgk/erythroid progenitor; MgK, megakaryocytes;
MKRP, Mgk-repopulating progenitors; MPP, multipotent progenitor; SL-MKP, stem-like Mgk committed progenitor; ST-HSC, short term HSC.
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biased/restricted HSCs, is also demonstrated. Although the physi-
ological roles of this unique class of cells in hematopoiesis and
hematologic diseases are still not fully elucidated (especially in the
human hematopoietic system), these ﬁndings provide new
insights into the hematopoietic regulatory mechanism.
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